Argenx Releases H1 2025 Financials and Q2 Business Highlights
Argenx, a global immunology company dedicated to improving the lives of people suffering from severe autoimmune diseases, has published its first-half 2025 financial results and second-quarter business highlights. The company’s robust pipeline development and strategic partnerships continue to shape its position as a biotech leader in rare diseases. Strong Revenue Growth Driven by Vyvgart Franchise…